Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 2
2000 2
2001 1
2002 2
2003 5
2004 1
2005 1
2006 1
2007 6
2008 4
2009 3
2010 7
2011 15
2012 12
2013 13
2014 17
2015 15
2016 22
2017 18
2018 12
2019 15
2020 22
2021 23
2022 26
2023 38
2024 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Results by year

Filters applied: . Clear all
Page 1
PRO-P: evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled trial.
Al-Monajjed R, Albers P, Droop J, Fugmann D, Noldus J, Palisaar RJ, Ritter M, Ellinger J, Krausewitz P, Truß M, Hadaschik B, Grünwald V, Schrader AJ, Papavassilis P, Ernstmann N, Schellenberger B, Moritz A, Kowalski C, Hellmich M, Heiden P, Hagemeier A, Horenkamp-Sonntag D, Giessing M, Pauler L, Dieng S, Peters M, Feick G, Karger A; PRO-P study group. Al-Monajjed R, et al. Among authors: grunwald v. Trials. 2024 Nov 12;25(1):754. doi: 10.1186/s13063-024-08579-8. Trials. 2024. PMID: 39533412 Free PMC article.
Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors.
Watanabe M, Fendler WP, Grafe H, Hirmas N, Hamacher R, Lanzafame H, Pabst KM, Hautzel H, Aigner C, Kasper S, von Tresckow B, Stuschke M, Kümmel S, Lugnier C, Hadaschik B, Grünwald V, Zarrad F, Kersting D, Siveke JT, Herrmann K, Weber M. Watanabe M, et al. Among authors: grunwald v. Ann Nucl Med. 2024 Oct 23. doi: 10.1007/s12149-024-01993-7. Online ahead of print. Ann Nucl Med. 2024. PMID: 39443386
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Sweis RF, et al. Among authors: grunwald v. JAMA Oncol. 2024 Nov;10(11):1565-1570. doi: 10.1001/jamaoncol.2024.3900. Epub 2024 Sep 19. JAMA Oncol. 2024. PMID: 39298147 Free PMC article. Clinical Trial.
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.
Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthélémy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, Nair SG, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grünwald V. Motzer RJ, et al. Among authors: grunwald v. J Clin Oncol. 2024 Sep 20:JCO2400773. doi: 10.1200/JCO.24.00773. Online ahead of print. J Clin Oncol. 2024. PMID: 39303200
281 results